RxDoctor Payments DataLook up a doctor →

Thomas Fiel, DO

Sports Medicine · Tempe, AZNPI 1235134552

Payments from drug & device makers

$23,492,325in general payments, 2019–2025

Across 2,372 payments — averaging $9904.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$15.5M
  • Modernatx, Inc.$2.9M
  • Pfizer$1.7M
  • Merck$1.2M
  • GSK$548K
  • Bavarian Nordic A/s$440K
  • plus $1.2M from 54 others
$103,187in research payments, 2019–2025

Across 4 payments — averaging $25,797 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$103K

What the payments were for

  • Speaking & faculty fees$6,00042%
  • Food & beverage$8,34958%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca43$15,485,309
Modernatx, Inc.1,290$2,915,031
Pfizer168$1,681,692
Merck29$1,204,528
GSK50$548,285
Bavarian Nordic A/s90$440,186
AbbVie(2 entities)88$269,465
Eli Lilly7$247,904
Genentech, Inc.46$170,877
Novartis25$156,824
Janssen Research & Development, LLC25$135,213
Currax Pharmaceuticals LLC34$90,448
Cipla USA Inc.30$38,554
Alnylam Pharmaceuticals Inc.74$28,549
Boehringer Ingelheim49$19,000
Urovant Sciences Inc3$19,000
Sumitomo Pharma America, Inc.9$11,128
Novo Nordisk AS5$8,500
Boehringer Ingelheim Pharma GmbH & Co.kg1$6,677
Seqirus USA Inc1$5,500
E.r. Squibb & Sons, L.L.C.1$1,807
Regeneron1$1,050
Boehringer Ingelheim International GmbH9$767
Lilly USA, LLC38$742
Astrazeneca UK Limited1$714
Novo Nordisk42$636
Amgen(2 entities)23$407
Johnson & Johnson(2 entities)25$395
Eisai Inc.14$376
Abbott14$294
Kowa Pharmaceuticals America, Inc.16$221
Fidia Pharma USA Inc.10$197
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC9$136
Pacira Therapeutics, Inc.5$135
Teva Pharmaceuticals USA, Inc.7$123
Boston Scientific6$113
Bioventus LLC2$90
Antares Pharma, Inc.5$87
Lucid Diagnostics Inc.3$83
Team_makena_llc3$83
Amarin Pharma, Inc.6$83
Clarus Therapeutics Inc.7$82
Arbor Pharmaceuticals, Inc.5$81
Takeda Pharmaceuticals U.S.A., Inc.4$63
Radius Health, Inc.3$61
Bayer4$59
Lundbeck LLC2$57
Exact Sciences3$55
Intra-sana Laboratories3$53
IBSA Pharma Inc.3$44
Sanofi-aventis U.S. LLC3$43
Esperion Therapeutics, Inc.2$40
Corcept Therapeutics2$39
Tolmar, Inc.2$38
Saluda Medical Americas, Inc.1$37
Idorsia Pharmaceuticals US Inc2$30
DJO, LLC1$30
Alfasigma USA, Inc.2$27
Gilead2$27
Galderma Laboratories, L.p.1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,492,325 in reported general payments places this provider in the 95th percentile of 152 sports medicine providers in Arizona.

See all sports medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$312,827
Medicare patients
497
Services billed
12,267

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide62$93,542
TrulicityDulaglutide40$65,326
XareltoRivaroxaban36$41,897
JardianceEmpagliflozin26$33,468
MounjaroTirzepatide23$27,869
FarxigaDapagliflozin Propanediol27$24,976
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$23,043
EliquisApixaban17$21,293
MyrbetriqMirabegron31$19,985
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$12,270
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,702
Insulin Lispro Kwikpen U-100Insulin Lispro17$4,737
SynthroidLevothyroxine Sodium28$2,153
Tamsulosin Hcl98$2,036
Rosuvastatin Calcium208$2,025

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$636$93,54262 claims
Lilly USA, LLCTrulicity, Mounjaro$742$93,19563 claims
Johnson & JohnsonXarelto$395$41,89736 claims
AstraZenecaFarxiga, Breztri Aerosphere$15,485,309$37,24641 claims
Boehringer IngelheimJardiance$19,000$33,46826 claims
GSKTrelegy Ellipta$548,285$23,04322 claims
PfizerEliquis$1,681,692$21,29317 claims
AbbVieSynthroid$269,465$2,15328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 152 sports medicine providers in Arizona.

Other sports medicine in Tempe

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →